Polycystic Kidney, Autosomal Dominant clinical trials at UC Health
1 in progress, 0 open to new patients
A Safety, Pharmacokinetic and Dose-Escalation Study of KD019 in Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Sorry, in progress, not accepting new patients
The primary objective of this study is to determine the safety, plasma pharmacokinetics, and maximum tolerated dose (MTD) of KD019 when administered to subjects with ADPKD.